rearrangement	amino_acid	frame_type	rearrangement_type	templates	reads	frequency	productive_frequency	cdr3_length	v_family	v_gene	v_allele	d_family	d_gene	d_allele	j_family	j_gene	j_allele	v_deletions	d5_deletions	d3_deletions	j_deletions	n2_insertions	n1_insertions	v_index	n1_index	n2_index	d_index	j_index	v_family_ties	v_gene_ties	v_allele_ties	d_family_ties	d_gene_ties	d_allele_ties	j_family_ties	j_gene_ties	j_allele_ties	sequence_tags	v_shm_count	v_shm_indexes	antibody	bio_identity	v_resolved	d_resolved	j_resolved	sample_name	species	locus	product_subtype	kit_pool	sku	test_name	sample_catalog_tags	sample_rich_tags	sample_rich_tags_json	kit_control	total_templates	productive_templates	outofframe_templates	stop_templates	dj_templates	total_rearrangements	productive_rearrangements	outofframe_rearrangements	stop_rearrangements	dj_rearrangements	total_reads	total_productive_reads	total_outofframe_reads	total_stop_reads	total_dj_reads	productive_clonality	productive_entropy	sample_clonality	sample_entropy	sample_amount_ng	sample_cells_mass_estimate	fraction_productive_of_cells_mass_estimate	sample_cells	fraction_productive_of_cells	max_productive_frequency	max_frequency	counting_method	primer_set	sequence_result_status	release_date	upload_date	sample_tags	fraction_productive	order_name	kit_id	total_t_cells	total_templates_agg
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGTGGGGCGACAGGTCGGTTAGAGACCCAGTACTTCGGGCCA	CASSGATGRLETQYF	In	VDJ	1	22	0.005112712061352545	0.007692307692307693	45	TCRBV21	TCRBV21-or09_02	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	6	2	4	4	6	6	24	35	47	41	53														CASSGATGRLETQYF+TCRBV21-or09_02+TCRBJ02-05	TCRBV21-or09_02*01	TCRBD01-01*01	TCRBJ02-05*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCCCTACAGGGGAGGGTGGTACAATGAGCAGTTCTTCGGGCCA	CASSPYRGGWYNEQFF	In	VDJ	1	24	0.005577504066930049	0.008391608391608392	48	TCRBV21	TCRBV21-or09_02	01				TCRBJ02	TCRBJ02-01	01	5	3	2	4	4	7	24	36	47	40	54				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSPYRGGWYNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01		TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGAGGACCATTGTATGGCGTGAGTGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	28	0.006507088078085057		56	TCRBV21	TCRBV21-or09_02	01				TCRBJ01	TCRBJ01-02	01	6	1	7	4	1	24	24	35	40	36	64				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV21-or09_02+TCRBJ01-02	TCRBV21-or09_02*01		TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGGCACTCGGAAGTCTGAGTGAAAGACCTATGGCTACACCTTCGGTTCG	CASSGTRKSE*KTYGYTF	Stop	VDJ	1	35	0.008133860097606322		54	TCRBV21	TCRBV21-or09_02	01				TCRBJ01	TCRBJ01-02	01	5	1	8	4	7	16	24	36	46	43	62				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSGTRKSE*KTYGYTF+TCRBV21-or09_02+TCRBJ01-02	TCRBV21-or09_02*01		TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCGTAGAGGGAACCCAGAGGGAGACCCAGTACTTCGGGCCA	CASSVEGTQRETQYF	In	VDJ	1	39	0.00906344410876133	0.013636363636363636	45	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-05	01	5	11	0	5	3	10	24	36	44	39	54														CASSVEGTQRETQYF+TCRBV21-or09_02+TCRBJ02-05	TCRBV21-or09_02*01	TCRBD02-01*02	TCRBJ02-05*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGAAATCGCATGCTACAAGGTGCATAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	49	0.01138740413664885		52	TCRBV21	TCRBV21-or09_02	01				TCRBJ01	TCRBJ01-04	01	6	3	6	4	12	7	24	35	50	47	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV21-or09_02+TCRBJ01-04	TCRBV21-or09_02*01		TCRBJ01-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TCAGGAGACACAGCACGGTATTTCTGTGCCAGCAGCCCCTTAGAGTCCTACAATGAGCAGTTCTTCGGGCCA	CASSPLESYNEQFF	In	VDJ	1	57	0.013246572158958867	0.01993006993006993	42	TCRBV21	TCRBV21-or09_02	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	5	8	1	4	2	24	36	43	40	45						01,02								CASSPLESYNEQFF+TCRBV21-or09_02+TCRBJ02-01	TCRBV21-or09_02*01	TCRBD02-01	TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CGACTCGGCTGTGTATCTCTGTGCCAGCAGCCGCCCCTTGAGTAGAGGGGTGGGCGGCGAGCAGTACTTCGGGCCG	CASSRPLSRGVGGEQYF	In	VDJ	1	21	0.004880316058563793	0.0073426573426573424	51	TCRBV07	TCRBV07-05	01				TCRBJ02	TCRBJ02-07	01	4	5	2	6	14	7	19	31	50	45	57				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRPLSRGVGGEQYF+TCRBV07-05+TCRBJ02-07	TCRBV07-05*01		TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TCCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTAATACAGGGGGCGCGGGAAAACTGTTTTTTGGCAGT	CAWSNTGGAGKLFF	In	VDJ	1	27	0.006274692075296305	0.00944055944055944	42	TCRBV30	TCRBV30-01	02	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	2	3	0	10	3	5	26	38	50	41	55													Vb 20	CAWSNTGGAGKLFF+TCRBV30-01+TCRBJ01-04	TCRBV30-01*02	TCRBD01-01*01	TCRBJ01-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCTGGAGTGTACCGGCAGGGCGGGATGGCTACACCTTCGGTTCG	CAWSVPAGRDGYTF	In	VDJ	1	40	0.009295840111550081	0.013986013986013986	42	TCRBV30	TCRBV30-01	01				TCRBJ01	TCRBJ01-02	01	0	4	3	6	5	4	26	40	50	45	54			unresolved	TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 20	CAWSVPAGRDGYTF+TCRBV30-01+TCRBJ01-02	TCRBV30-01*01		TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TYCTCAGTGACTCTGGCTTCTATCTCTGTGCCAGACACAGGTTCCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	46	0.010690216128282594		35	TCRBV30	TCRBV30-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	8	3	4	2	4	3	26	32	41	36	44			unresolved										Vb 20	X+TCRBV30-01+TCRBJ02-07	TCRBV30-01*01	TCRBD01-01*01	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TTCTCAGTGACTCTGGCTTCTATCTCTGTGCCGAGGAGGGCGAGGGGTCGAACTAATGAAAAACTGTTTTTTGGCAGT		Out	VDJ	1	71	0.016500116198001395		46	TCRBV30	TCRBV30-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	8	10	0	1	2	10	26	32	40	34	50													Vb 20	X+TCRBV30-01+TCRBJ01-04	TCRBV30-01*01	TCRBD02-01*02	TCRBJ01-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTTTAGATCTAAACTATGGCTACACCTTCGGTTCG	CASSLDLNYGYTF	In	VDJ	1	23	0.005345108064141297	0.008041958041958041	39	TCRBV28	TCRBV28-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-02	01	2	4	9	2	3	0	25	40	-1	43	46						01,02							Vb 3	CASSLDLNYGYTF+TCRBV28-01+TCRBJ01-02	TCRBV28-01*01	TCRBD02-01	TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CACCAACCAGACATCTATGTACCTCTGTGCCAGCAGTCCAAAGTTTCTTGACACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	56	0.013014176156170114		55	TCRBV28	TCRBV28-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	2	6	5	12	7	25	37	53	49	60													Vb 3	X+TCRBV28-01+TCRBJ02-06	TCRBV28-01*01	TCRBD01-01*01	TCRBJ02-06*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCATCAGTGAGTACATCTTAGATACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	74	0.017197304206367652		55	TCRBV10	TCRBV10-03	01				TCRBJ02	TCRBJ02-06	01	1	3	6	5	0	16	23	-1	42	39	58				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 12	X+TCRBV10-03+TCRBJ02-06	TCRBV10-03*01		TCRBJ02-06*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTATAGTAGGGGGCAATAACTATGGCTACACCTTCGGTTCG	CASSIVGGNNYGYTF	In	VDJ	1	34	0.007901464094817569	0.011888111888111888	45	TCRBV19	TCRBV19-01		TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	1	5	0	1	1	2	27	43	51	44	53			01,02										Vb 17	CASSIVGGNNYGYTF+TCRBV19-01+TCRBJ01-02	TCRBV19-01	TCRBD01-01*01	TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CAAAAGAACCCGACAGCTTTCTATCTCTGTGCCAGTAGTTACATTGCGGGAAGTTCGAGGGACAATGAGCAGTTCTTCGGGCCA	CASSYIAGSSRDNEQFF	In	VDJ	1	50	0.011619800139437602	0.017482517482517484	51	TCRBV19	TCRBV19-01		TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	5	7	3	5	6	10	27	39	51	45	61			01,02										Vb 17	CASSYIAGSSRDNEQFF+TCRBV19-01+TCRBJ02-01	TCRBV19-01	TCRBD02-01*02	TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACTAGCGGGGGCTACAATGAGCAGTTCTTCGGGCCA	CSATSGGYNEQFF	In	VDJ	1	22	0.005112712061352545	0.007692307692307693	39	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-01	01	4	4	2	3	0	0	26	-1	-1	36	46		TCRBV20-01,TCRBV20-or09_02												CSATSGGYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*01	TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GGACTCAGCCATGTATCGCTGTGCCAGCAGCTACGGGATAGCCTATGGAAAACTGTTTTTTGGCAGT	CASSYGIAYGKLFF	In	VDJ	1	23	0.005345108064141297	0.008041958041958041	42	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	4	8	3	10	1	10	19	32	38	33	48	TCRBV05,TCRBV07													CASSYGIAYGKLFF+X+TCRBJ01-04	unresolved	TCRBD02-01*02	TCRBJ01-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GGACTCGGCCCTTTATCTTTGCCAGCAGCTACGGGATAGCCTATGGAAAACTGTTTTTTGGCAGT		Out	VDJ	1	23	0.005345108064141297		42	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	4	8	3	10	1	10	17	30	36	31	46	TCRBV05,TCRBV07													X+X+TCRBJ01-04	unresolved	TCRBD02-01*02	TCRBJ01-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGAAAACACTGAAGCTTTCTTTGGACAA	CSARENTEAFF	In	VDJ	1	24	0.005577504066930049	0.008391608391608392	33	TCRBV20						TCRBJ01	TCRBJ01-01	01	3	1	8	2	0	1	26	-1	40	37	41		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARENTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20		TCRBJ01-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TCAGGAGACWCRGCMSKGTATYTCTGTGCCAGCAGATAGACCGGACAGCACGGCGAGCAGTACTTCGGGCCG	CASR*TGQHGEQYF	Stop	VDJ	1	24	0.005577504066930049		42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	1	5	6	7	5	18	29	42	36	47	TCRBV11,TCRBV21													CASR*TGQHGEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TCAGGAGACWCRGCMSKGTATKTCTGTGCCGGCAGGACAGCATTGGGATACAATGAGCAGTTCTTCGGGCCA	CAGRTALGYNEQFF	In	VDJ	1	24	0.005577504066930049	0.008391608391608392	42	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	11	1	5	4	4	8	24	30	40	34	48	TCRBV11,TCRBV12,TCRBV21													CAGRTALGYNEQFF+X+TCRBJ02-01	unresolved	TCRBD01-01*01	TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TYRGRRGACWCAGCMMKGTAYTTCTGTGCCAGCAGTGAAAGGAGCCAGGGAAGGTATGGCTACACCTTCGGTTCG	CASSERSQGRYGYTF	In	VDJ	1	24	0.005577504066930049	0.008391608391608392	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	2	4	3	5	6	4	23	38	49	44	53	TCRBV02,TCRBV21													CASSERSQGRYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ASCTCCCAGACATCTGTGTACTTSTGTGCCAGCACAACCGACAGGGGGCGGATTAACGAGCAGTACTTCGGGCCG	CASTTDRGRINEQYF	In	VDJ	1	26	0.006042296072507553	0.00909090909090909	45	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	7	2	0	5	5	6	23	33	48	38	54	TCRBV06,TCRBV10													CASTTDRGRINEQYF+X+TCRBJ02-07	unresolved	TCRBD01-01*01	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTTCGCGGCTAGTTTTTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	27	0.006274692075296305		43	TCRBV12			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	3	4	8	4	6	4	26	40	50	46	54		TCRBV12-03,TCRBV12-04				01,02								X+TCRBV12-X+TCRBJ02-07	TCRBV12	TCRBD02-01	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CAGGGACTCAGCTGTGTACTTCTGTGCCAGCAGTCATGGCGATTACATGAAAGACCTATGGCTACACCTTCGGTTCG		Out	VDJ	1	27	0.006274692075296305		49	TCRBV12						TCRBJ01	TCRBJ01-02	01	5	2	7	4	18	0	22	34	-1	52	55		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-X+TCRBJ01-02	TCRBV12		TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCTCAGAATTCAGGGGTTTCTCTGAAGCTTTCTTTGGACAA	CASSSEFRGFSEAFF	In	VDJ	1	29	0.006739484080873809	0.01013986013986014	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	6	4	2	6	9	5	26	37	52	46	57		TCRBV12-03,TCRBV12-04,TCRBV12-05												CASSSEFRGFSEAFF+TCRBV12-X+TCRBJ01-01	TCRBV12	TCRBD01-01*01	TCRBJ01-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCAGGATTCCTAGCGGGAGCAAGTAATGAGCAGTTCTTCGGGCCA	CSAPGFLAGASNEQFF	In	VDJ	1	29	0.006739484080873809	0.01013986013986014	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	6	4	2	7	10	5	26	34	54	44	59		TCRBV20-01,TCRBV20-or09_02												CSAPGFLAGASNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GGACTCGGCCCTCTATCTCTGTGCCAGAAGCAGATTTTCTCCAGGGGGGATACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	29	0.006739484080873809		49	TCRBV05			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	4	1	4	10	2	19	31	48	41	50		TCRBV05-03,TCRBV05-06,TCRBV05-07												X+TCRBV05-X+TCRBJ02-01	TCRBV05	TCRBD01-01*01	TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCTCCTTAGCGGGAGGGCTTCCGAGCAGTACTTCGGGCCG	CASSLLSGRASEQYF	In	VDJ	1	30	0.006971880083662561	0.01048951048951049	45	TCRBV03			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-07	01	4	5	0	6	4	4	26	39	54	43	58		TCRBV03-01,TCRBV03-02												CASSLLSGRASEQYF+TCRBV03-X+TCRBJ02-07	TCRBV03	TCRBD02-01*02	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGAAGGGACCTTTAGCTCTGGAAACACCATATATTTTGGAGAG	CASSLEGTFSSGNTIYF	In	VDJ	1	32	0.007436672089240065	0.011188811188811189	49	unresolved						TCRBJ01	TCRBJ01-03	01	13	0	7	0	13	6	20	23	41	36	47	TCRBV05,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSLEGTFSSGNTIYF+X+TCRBJ01-03	unresolved		TCRBJ01-03*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GGACTCGGCCSTSTATSTCTGTGCCAGCAGCTTGGACCGGGACAGTAACACCGGGGAGCTGTTTTTTGGAGAA	CASSLDRDSNTGELFF	In	VDJ	1	32	0.007436672089240065	0.011188811188811189	48	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-02	01	3	0	5	2	5	1	18	32	44	37	45	TCRBV05,TCRBV11													CASSLDRDSNTGELFF+X+TCRBJ02-02	unresolved	TCRBD01-01*01	TCRBJ02-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCCGTCAGGCGCCCGCAGATACGCAGTATTTTGGCCCA	CASSRQAPADTQYF	In	VDJ	1	32	0.007436672089240065	0.011188811188811189	42	TCRBV05			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	4	4	4	4	3	6	19	31	38	34	44		TCRBV05-06,TCRBV05-07												CASSRQAPADTQYF+TCRBV05-X+TCRBJ02-03	TCRBV05	TCRBD01-01*01	TCRBJ02-03*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GGACTCGGCCCTTTATCTTTGCCAGCAGCTTGGAAGGGACCTTTAGCTCTGGAAACACCATATATTTTGGAGAG		Out	VDJ	1	32	0.007436672089240065		49	unresolved						TCRBJ01	TCRBJ01-03	01	13	0	7	0	13	6	19	22	40	35	46	TCRBV05,TCRBV11			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+X+TCRBJ01-03	unresolved		TCRBJ01-03*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTACCAGCAGTTTAGTCCTAGCGGGGGGGCCCTCGGAGACCCAGTACTTCGGGCCA	CTSSLVLAGGPSETQYF	In	VDJ	1	33	0.007669068092028817	0.011538461538461539	51	TCRBV12			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	1	4	0	5	2	6	26	42	56	44	62		TCRBV12-03,TCRBV12-04												CTSSLVLAGGPSETQYF+TCRBV12-X+TCRBJ02-05	TCRBV12	TCRBD02-01*01	TCRBJ02-05*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGCGCACACCATCCATTTGCAAAGAAAAAACATTCAGTACTTCGGCGCC		Out	VDJ	1	33	0.007669068092028817		52	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-04	01	6	3	6	4	3	17	26	37	43	40	60		TCRBV12-03,TCRBV12-04,TCRBV12-05												X+TCRBV12-X+TCRBJ02-04	TCRBV12	TCRBD01-01*01	TCRBJ02-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGATTGTTCGGGAGTGGCTCCTACAATGAGCAGTTCTTCGGGCCA	CSARLFGSGSYNEQFF	In	VDJ	1	34	0.007901464094817569	0.011888111888111888	48	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-01	01	2	8	2	0	5	3	26	38	49	43	52		TCRBV20-01,TCRBV20-or09_02												CSARLFGSGSYNEQFF+TCRBV20-X+TCRBJ02-01	TCRBV20	TCRBD02-01*02	TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTTACAGGGGGCACACTGAAGCTTTCTTTGGACAA	CSAYRGHTEAFF	In	VDJ	1	36	0.008366256100395073	0.012587412587412588	36	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	3	0	3	1	0	26	35	-1	36	45		TCRBV20-01,TCRBV20-or09_02												CSAYRGHTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GGACTCGGCCCTCTATCTCTGTGCCAGCAGCCACGAACAGGGGCCCTATCCCTACAATGAGCAGTTCTTCGGGCCA	CASSHEQGPYPYNEQFF	In	VDJ	1	37	0.008598652103183826	0.012937062937062937	51	TCRBV05			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	4	3	2	2	5	7	19	31	43	36	50		TCRBV05-06,TCRBV05-07												CASSHEQGPYPYNEQFF+TCRBV05-X+TCRBJ02-01	TCRBV05	TCRBD01-01*01	TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGTGCGGGGGCTGGGTATGGCTACACCTTCGGTTCG	CSASAGAGYGYTF	In	VDJ	1	39	0.00906344410876133	0.013636363636363636	39	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	3	7	2	5	1	5	26	37	45	38	50		TCRBV20-01,TCRBV20-or09_02												CSASAGAGYGYTF+TCRBV20-X+TCRBJ01-02	TCRBV20	TCRBD02-01*01	TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGTAAGGGGGCCCTGGACACTGAAGCTTTCTTTGGACAA		Out	VDJ	1	41	0.009528236114338834		44	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	5	0	3	2	5	26	39	48	41	53		TCRBV20-01,TCRBV20-or09_02												X+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TYRGGRGACWCAGCWYKGTATTTCTGTGCCAGCAGGGAGGGGTTCACCGGGGAGCTGTTTTTTGGAGAA	CASREGFTGELFF	In	VDJ	1	45	0.010457820125493842	0.015734265734265736	39	unresolved			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	6	10	0	4	0	3	24	-1	41	35	44	TCRBV09,TCRBV21													CASREGFTGELFF+X+TCRBJ02-02	unresolved	TCRBD02-01*02	TCRBJ02-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATGTAAGTTCGCAAGAGACCCAGTACTTCGGGCCA	CSARDVSSQETQYF	In	VDJ	1	50	0.011619800139437602	0.017482517482517484	42	TCRBV20						TCRBJ02	TCRBJ02-05	01	0	5	5	2	4	4	26	40	46	44	50		TCRBV20-01,TCRBV20-or09_02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CSARDVSSQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20		TCRBJ02-05*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTTTATCGGACAGGGGATTAATGAGCAGTTCTTCGGGCCA	CASSFIGQGINEQFF	In	VDJ	1	51	0.011852196142226355	0.01783216783216783	45	TCRBV12			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-01	01	3	1	2	7	4	3	26	40	53	44	56		TCRBV12-03,TCRBV12-04												CASSFIGQGINEQFF+TCRBV12-X+TCRBJ02-01	TCRBV12	TCRBD01-01*01	TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGGAACAGGGGGCGTGAACACTGAAGCTTTCTTTGGACAA	CSGTGGVNTEAFF	In	VDJ	1	52	0.012084592145015106	0.01818181818181818	39	TCRBV20			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	3	0	0	2	1	26	33	44	35	45		TCRBV20-01,TCRBV20-or09_02												CSGTGGVNTEAFF+TCRBV20-X+TCRBJ01-01	TCRBV20	TCRBD01-01*01	TCRBJ01-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCCTAGCGGGGAGAGACAAGAGACCCAGTACTTCGGGCCA	CSARDPSGERQETQYF	In	VDJ	1	53	0.012316988147803859	0.01853146853146853	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	4	3	2	2	5	26	40	51	42	56		TCRBV20-01,TCRBV20-or09_02												CSARDPSGERQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGGGACTAGCGGTTATTACCCGGGGAGCTGTTTTTTGGAGAA	CSARD*RLLPGELFF	Stop	VDJ	1	53	0.012316988147803859		45	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-02	01	3	1	5	6	0	7	26	-1	47	37	54		TCRBV20-01,TCRBV20-or09_02				01,02								CSARD*RLLPGELFF+TCRBV20-X+TCRBJ02-02	TCRBV20	TCRBD02-01	TCRBJ02-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CAACCAGACAGCTCTTTACTTCTGTGCCACCAGTGATCGACTAGCGGGAGTCCTCCTTCAAACACCGGGGAGCTGTTTTTTGGAGAA		Out	VDJ	1	53	0.012316988147803859		59	TCRBV24			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-02	01	3	2	2	2	1	10	22	37	50	38	60		TCRBV24-01,TCRBV24-or09_02												X+TCRBV24-X+TCRBJ02-02	TCRBV24	TCRBD02-01*02	TCRBJ02-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTACTCAAGGGAGGATAGGCAAAAACATTCAGTACTTCGGCGCC	CSATQGRIGKNIQYF	In	VDJ	1	55	0.012781780153381363	0.019230769230769232	45	TCRBV20			TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-04	01	4	9	1	3	5	5	26	36	47	41	52		TCRBV20-01,TCRBV20-or09_02												CSATQGRIGKNIQYF+TCRBV20-X+TCRBJ02-04	TCRBV20	TCRBD02-01*02	TCRBJ02-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGTCGGGACAGGCCAAAGTGAAAAACTGTTTTTTGGCAGT	CASSQVGTGQSEKLFF	In	VDJ	1	58	0.013478968161747618	0.02027972027972028	48	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	1	0	4	7	2	6	26	42	52	44	58		TCRBV03-01,TCRBV03-02												CASSQVGTGQSEKLFF+TCRBV03-X+TCRBJ01-04	TCRBV03	TCRBD01-01*01	TCRBJ01-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCCCCGTCGGTAGCACAGATACGCAGTATTTTGGCCCA	CSAPVGSTDTQYF	In	VDJ	1	61	0.014176156170113875	0.02132867132867133	39	TCRBV20			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	6	8	5	0	6	1	26	34	43	40	44		TCRBV20-01,TCRBV20-or09_02				01,02								CSAPVGSTDTQYF+TCRBV20-X+TCRBJ02-03	TCRBV20	TCRBD02-01	TCRBJ02-03*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGAAAGGATGTCCAGTACTTCGGGCCA	CASSQGKDVQYF	In	VDJ	1	64	0.01487334417848013	0.022377622377622378	36	TCRBV03						TCRBJ02	TCRBJ02-05	01	1	1	8	10	4	3	26	42	49	46	52		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQGKDVQYF+TCRBV03-X+TCRBJ02-05	TCRBV03		TCRBJ02-05*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
TYRGRRGACWCAGCMMKGTAYTTCTGTGCCATCACTTCTCCCTTAGGGTACAGCTACGAGCAGTACTTCGGGCCG	CAITSPLGYSYEQYF	In	VDJ	1	65	0.015105740181268883	0.022727272727272728	45	unresolved						TCRBJ02	TCRBJ02-07	01	10	3	5	3	18	0	23	30	-1	48	52	TCRBV02,TCRBV21			TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CAITSPLGYSYEQYF+X+TCRBJ02-07	unresolved		TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCATTCATGCAAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	66	0.015338136184057634		37	TCRBV03						TCRBJ02	TCRBJ02-03	01	5	4	6	5	3	4	26	38	43	41	47		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ02-03	TCRBV03		TCRBJ02-03*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
ATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCTAGAGATCTTAGCGGGGGATTACAAGAGACCCAGTACTTCGGGCCA	CSARDLSGGLQETQYF	In	VDJ	1	69	0.01603532419242389	0.024125874125874126	48	TCRBV20			TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	0	5	2	2	3	4	26	40	52	43	56		TCRBV20-01,TCRBV20-or09_02												CSARDLSGGLQETQYF+TCRBV20-X+TCRBJ02-05	TCRBV20	TCRBD02-01*01	TCRBJ02-05*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAACACTGGGCGTCTGCAACGAGCAGTACTTCGGGCCG		Out	VDJ	1	71	0.016500116198001395		44	TCRBV06			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	2	8	0	5	4	7	23	38	46	42	53		TCRBV06-01,TCRBV06-08												X+TCRBV06-X+TCRBJ02-07	TCRBV06	TCRBD01-01*01	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCATTACGGGTCCCTCCATTCCGACAATGAGCAGTTCTTCGGGCCA		Out	VDJ	1	79	0.01835928422031141		50	TCRBV03			TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-01	01	5	8	4	5	4	13	26	38	46	42	59		TCRBV03-01,TCRBV03-02				01,02								X+TCRBV03-X+TCRBJ02-01	TCRBV03	TCRBD02-01	TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AGCACCAACCAGACATCTRTGTAYCTCTRTGCCAGCAGTAGGCCTCTCTTGACACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC	XASSRPLLTQSRANVLTF	In	VDJ	1	82	0.01905647222867767	0.028671328671328673	54	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	2	6	5	11	7	25	37	52	48	59	TCRBV26,TCRBV28													XASSRPLLTQSRANVLTF+X+TCRBJ02-06	unresolved	TCRBD01-01*01	TCRBJ02-06*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCCAAGGTGCAGGGAACACTGAAGCTTTCTTTGGACAA	CASSQGAGNTEAFF	In	VDJ	1	88	0.02045084824541018	0.03076923076923077	42	TCRBV03			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	1	4	4	1	3	0	26	42	-1	45	49		TCRBV03-01,TCRBV03-02												CASSQGAGNTEAFF+TCRBV03-X+TCRBJ01-01	TCRBV03	TCRBD01-01*01	TCRBJ01-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AGCTTGGTGACTCTGCTGTGTATTTCTGTGCCAGCAGCATAAGCAATTTTACACGCACGAAACACCATATATTTTGGAGAG		Out	VDJ	2	106	0.024633976295607717		49	TCRBV03						TCRBJ01	TCRBJ01-03	01	5	3	6	5	12	5	26	38	53	50	58		TCRBV03-01,TCRBV03-02		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV03-X+TCRBJ01-03	TCRBV03		TCRBJ01-03*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAGTTGCGATAGGGAAAACTGTTTTTTGGCAGT		Out	VDJ	2	122	0.02835231234022775		35	TCRBV12						TCRBJ01	TCRBJ01-04	01	4	5	3	10	5	0	26	39	-1	44	48		TCRBV12-03,TCRBV12-04		TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV12-X+TCRBJ01-04	TCRBV12		TCRBJ01-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
MAGAAGACTCAGCYSYGTATCTCTGCGCCAGCAGCGGACAGAACTATGGCTACACCTTCGGTTCG	CASSGQNYGYTF	In	VDJ	3	174	0.040436904485242856	0.06083916083916084	36	unresolved			TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	5	1	5	2	0	0	23	-1	-1	35	41	TCRBV01,TCRBV04													CASSGQNYGYTF+X+TCRBJ01-02	unresolved	TCRBD01-01*01	TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGGGGACTACTCCTACGAGCAGTACTTCGGGCCG	CSVGDYSYEQYF	In	VDJ	1	21	0.004880316058563793	0.0073426573426573424	36	TCRBV29	TCRBV29-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	4	0	9	0	0	0	25	-1	-1	35	42						01,02							Vb 4	CSVGDYSYEQYF+TCRBV29-01+TCRBJ02-07	TCRBV29-01*01	TCRBD02-01	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCCTGAAGACAGCAGCATATATCTCTGCAGCGTTGAAGATTGGGGACAGGGAACAGATACGCAGTATTTTGGCCCA	CSVEDWGQGTDTQYF	In	VDJ	1	42	0.009760632117127585	0.014685314685314685	45	TCRBV29	TCRBV29-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	0	0	3	3	3	1	25	39	51	42	52													Vb 4	CSVEDWGQGTDTQYF+TCRBV29-01+TCRBJ02-03	TCRBV29-01*01	TCRBD01-01*01	TCRBJ02-03*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AGCACCAACCAGACATCTGTGTATCTCTATGCCAGCAGTCTAGGACGCTCGTATGGCTACACCTTCGGTTCG	YASSLGRSYGYTF	In	VDJ	1	31	0.007204276086451313	0.010839160839160839	39	TCRBV26	TCRBV26-01	01				TCRBJ01	TCRBJ01-02	01	5	1	7	5	3	5	27	39	46	42	51				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									YASSLGRSYGYTF+TCRBV26-01+TCRBJ01-02	TCRBV26-01*01		TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GGACTCRGCCATGTATCGCTGTGCCAGCAGCTTAGGGACTTCGGGACTGGCCTACGAGCAGTACTTCGGGCCG	CASSLGTSGLAYEQYF	In	VDJ	1	27	0.006274692075296305	0.00944055944055944	48	TCRBV07	unresolved		TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	1	0	10	2	7	2	19	35	48	42	50		TCRBV07-06,TCRBV07-07				01,02								CASSLGTSGLAYEQYF+TCRBV07-X+TCRBJ02-07	unresolved	TCRBD02-01	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CTCCCTCYCAGACWTCTGTKTACTTSTGTGCCAGCAGTTACATCCTATTGGGGGGGCGAAGAGACCCAGTACTTCGGGCCA		Out	VDJ	1	28	0.006507088078085057		49	TCRBV06	unresolved		TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	2	9	0	3	8	2	23	38	53	46	55		TCRBV06-07,TCRBV06-08												X+TCRBV06-X+TCRBJ02-05	unresolved	TCRBD02-01*01	TCRBJ02-05*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCCAAGTGTGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC	CATSQV*QSRANVLTF	Stop	VDJ	1	25	0.005809900069718801		48	TCRBV15	TCRBV15-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-06	01	5	2	6	5	7	5	18	30	41	37	46														CATSQV*QSRANVLTF+TCRBV15-01+TCRBJ02-06	TCRBV15-01*01	TCRBD01-01*01	TCRBJ02-06*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GACGCAGCCATGTACCTGTGTGCCACCAGCAGAGAGGGGAGGAAGTGAAAAACTGTTTTTTGGCAGT		Out	VDJ	2	120	0.027887520334650244		43	TCRBV15	TCRBV15-01	01	TCRBD02	TCRBD02-01	02	TCRBJ01	TCRBJ01-04	01	0	9	1	7	1	3	18	35	42	36	45														X+TCRBV15-01+TCRBJ01-04	TCRBV15-01*01	TCRBD02-01*02	TCRBJ01-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTCACCGGACAGGGGGATGAAGACCCAGTACTTCGGGCCA	CASSSPDRGMKTQYF	In	VDJ	1	24	0.005577504066930049	0.008391608391608392	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-05	01	4	1	1	6	4	4	18	31	45	35	49														CASSSPDRGMKTQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD01-01*01	TCRBJ02-05*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCTTGGGACTAGCGGGGGGGCCTGTAGAGACCCAGTACTTCGGGCCA	CASSLGLAGGPVETQYF	In	VDJ	1	25	0.005809900069718801	0.008741258741258742	51	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ02	TCRBJ02-05	01	3	0	0	4	0	5	18	-1	48	32	53														CASSLGLAGGPVETQYF+TCRBV11-03+TCRBJ02-05	TCRBV11-03*01	TCRBD02-01*01	TCRBJ02-05*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCACCGTCGAGCGGAGCTACGAGCAGTACTTCGGGCCG	CASSTVERSYEQYF	In	VDJ	1	27	0.006274692075296305	0.00944055944055944	42	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	5	6	5	3	7	2	18	30	42	37	44						01,02								CASSTVERSYEQYF+TCRBV11-03+TCRBJ02-07	TCRBV11-03*01	TCRBD02-01	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCAAGCTCCAGGAACGAACACTGAAGCTTTCTTTGGACAA	CASSQAPGTNTEAFF	In	VDJ	1	35	0.008133860097606322	0.012237762237762238	45	TCRBV11	TCRBV11-03	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	5	4	4	1	7	3	18	30	41	37	44														CASSQAPGTNTEAFF+TCRBV11-03+TCRBJ01-01	TCRBV11-03*01	TCRBD01-01*01	TCRBJ01-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCGGCGGATCAGGAGACGACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC	CASSRRIRRRQSRANVLTF	In	VDJ	1	40	0.009295840111550081	0.013986013986013986	57	TCRBV11	TCRBV11-03	01				TCRBJ02	TCRBJ02-06	01	5	2	6	5	16	5	18	30	50	46	55				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSRRIRRRQSRANVLTF+TCRBV11-03+TCRBJ02-06	TCRBV11-03*01		TCRBJ02-06*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GACTCGGCCGTGTATGTCTGTGCCAGCAGCCCGGGGGGTTCAACTAATGAAAAACTGTTTTTTGGCAGT	CASSPGGSTNEKLFF	In	VDJ	1	65	0.015105740181268883	0.022727272727272728	45	TCRBV11	TCRBV11-03	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-04	01	5	8	1	0	1	2	18	30	38	31	40														CASSPGGSTNEKLFF+TCRBV11-03+TCRBJ01-04	TCRBV11-03*01	TCRBD02-01*01	TCRBJ01-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCCAGCAACAGGGATGGAAACACCATACATTTTGGAGAG	CASNRDGNTIHF	In	VDJ	1	25	0.005809900069718801	0.008741258741258742	36	TCRBV12	TCRBV12-05	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-03	01	12	3	3	17	5	15	26	31	42	36	57														CASNRDGNTIHF+TCRBV12-05+TCRBJ01-03	TCRBV12-05*01	TCRBD01-01*01	TCRBJ01-03*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
AACCCAGGGACTCAGCTGTGTATTTTTGTGCTAGTGGTTTGCACGACTACAGATTCCTACGAGCAGTACTTCGGGCCG		Out	VDJ	1	32	0.007436672089240065		46	TCRBV12	TCRBV12-05	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-07	01	2	2	9	1	3	5	26	41	49	44	54						01,02								X+TCRBV12-05+TCRBJ02-07	TCRBV12-05*01	TCRBD02-01	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCCAAGAGGTCTCGGGGCTAGATACGCAGTATTTTGGCCCA	CASSQEVSGLDTQYF	In	VDJ	1	27	0.006274692075296305	0.00944055944055944	45	TCRBV23	TCRBV23-01	01				TCRBJ02	TCRBJ02-03	01	2	7	0	5	8	1	20	35	48	43	49				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSQEVSGLDTQYF+TCRBV23-01+TCRBJ02-03	TCRBV23-01*01		TCRBJ02-03*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCTTGGGGCGGACTACAACTAATGAAAAACTGTTTTTTGGCAGT	CASSLGRTTTNEKLFF	In	VDJ	1	27	0.006274692075296305	0.00944055944055944	48	TCRBV23	TCRBV23-01	01	TCRBD02	TCRBD02-01		TCRBJ01	TCRBJ01-04	01	6	1	9	0	8	0	20	31	-1	39	45						01,02								CASSLGRTTTNEKLFF+TCRBV23-01+TCRBJ01-04	TCRBV23-01*01	TCRBD02-01	TCRBJ01-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
GAGACACGGCACTGTATCTCTGCGCCAGCAGCAACCGGGACACGCTAAAGGACGAGCAGTACTTCGGGCCG	CASSNRDTLKDEQYF	In	VDJ	1	28	0.006507088078085057	0.009790209790209791	45	TCRBV23	TCRBV23-01	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	6	0	6	5	5	9	20	31	42	36	51														CASSNRDTLKDEQYF+TCRBV23-01+TCRBJ02-07	TCRBV23-01*01	TCRBD01-01*01	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCTGGGGGGGCCAATGGCTACACCTTCGGTTCG	CASSYSGGANGYTF	In	VDJ	1	25	0.005809900069718801	0.008741258741258742	42	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	01	TCRBJ01	TCRBJ01-02	01	0	9	0	6	1	3	23	40	48	41	51														CASSYSGGANGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD02-01*01	TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACCGAGACCGAACAGGGGCCGACACTGAAGCTTTCTTTGGACAA	CASSYRDRTGADTEAFF	In	VDJ	1	30	0.006971880083662561	0.01048951048951049	51	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	2	3	2	3	9	3	23	38	54	47	57														CASSYRDRTGADTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTCCCGGGACCTATCCTTCTACGAGCAGTACTTCGGGCCG	CASSSRDLSFYEQYF	In	VDJ	1	31	0.007204276086451313	0.010839160839160839	45	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-07	01	4	0	7	3	3	8	23	36	44	39	52				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									CASSSRDLSFYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01		TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCACTGAGCGGACAGGGGGCTACGAGCAGTACTTCGGGCCG	CATERTGGYEQYF	In	VDJ	1	33	0.007669068092028817	0.011538461538461539	39	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-07	01	10	1	1	3	6	0	23	30	-1	36	46														CATERTGGYEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACTCGGCCAGATACTATGGCTACACCTTCGGTTCG	CASSYSARYYGYTF	In	VDJ	1	33	0.007669068092028817	0.011538461538461539	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-02	01	0	4	5	3	3	2	23	40	46	43	48														CASSYSARYYGYTF+TCRBV06-08+TCRBJ01-02	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-02*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCATCTTCGACAGGGGTAACACTGAAGCTTTCTTTGGACAA	CASIFDRGNTEAFF	In	VDJ	1	46	0.010690216128282594	0.016083916083916083	42	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-01	01	7	2	2	2	5	1	23	33	46	38	47														CASIFDRGNTEAFF+TCRBV06-08+TCRBJ01-01	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTACGGGCGGACAGGGGCAGATACGCAGTATTTTGGCCCA	CASSYGRTGADTQYF	In	VDJ	1	49	0.01138740413664885	0.017132867132867134	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ02	TCRBJ02-03	01	2	1	2	4	4	0	23	38	-1	42	51														CASSYGRTGADTQYF+TCRBV06-08+TCRBJ02-03	TCRBV06-08*01	TCRBD01-01*01	TCRBJ02-03*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGATTYGGGGCAGCAAGCGAGCAGTACTTCGGGCCG	CASRFGAASEQYF	In	VDJ	1	68	0.015802928189635138	0.023776223776223775	39	TCRBV06	TCRBV06-08	01	unresolved			TCRBJ02	TCRBJ02-07	01	6	7	0	6	4	6	23	34	43	38	49				TCRBD01,TCRBD02										CASRFGAASEQYF+TCRBV06-08+TCRBJ02-07	TCRBV06-08*01	unresolved	TCRBJ02-07*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTTTCATAGCAGGGGAAAATGAAAAACTGTTTTTTGGCAGT	CASSFIAGENEKLFF	In	VDJ	1	70	0.016267720195212644	0.024475524475524476	45	TCRBV06	TCRBV06-08	01	TCRBD01	TCRBD01-01	01	TCRBJ01	TCRBJ01-04	01	4	4	2	5	6	2	23	36	48	42	50														CASSFIAGENEKLFF+TCRBV06-08+TCRBJ01-04	TCRBV06-08*01	TCRBD01-01*01	TCRBJ01-04*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTAGTAATAGTGGGTGCTACAAAGTCGGGCCAACGTCCTGACTTTCGGGGCC		Out	VDJ	1	71	0.016500116198001395		56	TCRBV06	TCRBV06-08	01				TCRBJ02	TCRBJ02-06	01	5	0	9	5	9	12	23	35	47	44	59				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01									X+TCRBV06-08+TCRBJ02-06	TCRBV06-08*01		TCRBJ02-06*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CCTCCCAGACATCTGTGTACTTGTGTGCCAGCAGTGAGGGTCGCCCGGGGGCCAACGTCCTGACTTTCGGGGCC	CASSEGRPGANVLTF	In	VDJ	2	116	0.026957936323495236	0.04055944055944056	45	TCRBV06	TCRBV06-08	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	5	11	0	4	0	7	23	-1	40	35	47														CASSEGRPGANVLTF+TCRBV06-08+TCRBJ02-06	TCRBV06-08*01	TCRBD02-01*02	TCRBJ02-06*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCACCGCGGGCACAGATACGCAGTATTTTGGCCCA		Out	VDJ	1	22	0.005112712061352545		41	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01		TCRBJ02	TCRBJ02-03	01	0	7	5	1	0	0	24	-1	-1	41	45						01,02							Vb 18	X+TCRBV18-01+TCRBJ02-03	TCRBV18-01*01	TCRBD02-01	TCRBJ02-03*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACTTAGTTGGGATAATGAGCAGTTCTTCGGGCCA	CASSLSWDNEQFF	In	VDJ	1	40	0.009295840111550081	0.013986013986013986	39	TCRBV18	TCRBV18-01	01				TCRBJ02	TCRBJ02-01	01	4	0	8	7	6	1	24	37	47	43	48				TCRBD01,TCRBD02	TCRBD01-01,TCRBD02-01								Vb 18	CASSLSWDNEQFF+TCRBV18-01+TCRBJ02-01	TCRBV18-01*01		TCRBJ02-01*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
CGAGGAGATTCGGCAGCTTATTTCTGTGCCAGCTCACCCGCGTCATGGAGGTTAGGGCCTGGGGCCAACGTCCTGACTTTCGGGGCC	CASSPASWRLGPGANVLTF	In	VDJ	1	65	0.015105740181268883	0.022727272727272728	57	TCRBV18	TCRBV18-01	01	TCRBD02	TCRBD02-01	02	TCRBJ02	TCRBJ02-06	01	3	10	1	2	8	7	24	38	51	46	58													Vb 18	CASSPASWRLGPGANVLTF+TCRBV18-01+TCRBJ02-06	TCRBV18-01*01	TCRBD02-01*02	TCRBJ02-06*01	2050A	Human	TCRB	Survey		ISS10006	immunoSEQ hsTCRB-FFPE Service (Survey)	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor				101	67	30	3	0	95	67	24	4	0	4303	2860	1306	137	0	0.0303590503	5.88192844	0.0297094267	6.37466908				668	0.0972745717	0.0608391613	0.0404369049	v2	Human-TCRB-PD2x	Published	09/16/2016 03:39:39	09/06/2016 10:38:54	Age (Range):45-65 Years (Late Adulthood),Age:45 Years,Cancer:Ovarian Cancer,Preservation Type:FFPE,Species:Human,Tissue Source:Ovary,Tissue Source:Tissue,Tissue Source:Tumor,os censored status:os censored status 1,overall survival (days):overall survival (days) 661,pfs censored status:pfs censored status 1,progression free survival (days):progression free survival (days) 166,type of chemo:carbo/taxol	0.6633663185526708	MSKCC- Snyder- P01-02		65.0	
